Anzeige
Mehr »
Login
Mittwoch, 24.04.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Breaking News: InnoCan startet in eine neue Ära – FDA Zulassung!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2DLMU | ISIN: FR0013233475 | Ticker-Symbol: N/A
1-Jahres-Chart  (nicht börsennotiert)
LYSOGENE SA Chart 1 Jahr

Aktuelle News zur LYSOGENE

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
05.12.23XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 05.12.2023789The following instruments on Boerse Frankfurt do have their last trading day on 05.12.2023Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 05.12.2023ISIN NameAU000000FYI5 FYI...
► Artikel lesen
01.08.23Mucopolysaccharidosis Market to Accelerate Substantially, Predicts DelveInsight | Key Companies Working in the Market - Ultragenyx, Abeona, Homology Medicines, Denali, LYSOGENE, Allievex, Bellicum Pharmaceuticals, Shire, Takeda824The dynamics of the mucopolysaccharidosis market are anticipated to change in the coming years owing to improvement in the diagnosis methodologies, rising awareness of the disease, incremental...
► Artikel lesen
26.05.23Lysogene Announces the Conversion of the Reorganization Proceedings into Judicial Liquidation and its Delisting646Regulatory News: Lysogene (FR0013233475 LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, announces that the Commercial Court of Nanterre has decided...
► Artikel lesen
26.05.23Lysogene: Hearing Scheduled on May 23, 2023 on the Possible Opening of Judicial Liquidation Proceedings485Regulatory News: Lysogene (FR0013233475 LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, announces that on May 23, 2023, the Commercial Court of Nanterre...
► Artikel lesen
29.04.23Lysogene Announces Postponement of 2022 Financial Results Release632Regulatory News: Lysogene (FR0013233475 LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, announces that it will not be able to release its 2022 financial...
► Artikel lesen
5 Nachrichten in den letzten 12 Monaten